CY1118292T1 - Ρυθμιστες φαρμακοκινητικων ιδιοτητων των θεραπευτικων - Google Patents
Ρυθμιστες φαρμακοκινητικων ιδιοτητων των θεραπευτικωνInfo
- Publication number
- CY1118292T1 CY1118292T1 CY20161101075T CY161101075T CY1118292T1 CY 1118292 T1 CY1118292 T1 CY 1118292T1 CY 20161101075 T CY20161101075 T CY 20161101075T CY 161101075 T CY161101075 T CY 161101075T CY 1118292 T1 CY1118292 T1 CY 1118292T1
- Authority
- CY
- Cyprus
- Prior art keywords
- therapeutics
- regulators
- pharmaceutical properties
- compounds
- administering
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 4
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 239000002671 adjuvant Substances 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Η παρούσα δήλωση παρέχει ένωση του Τύπου IV, ή φαρμακευτικώς αποδεκτό άλας, διαλύτωμα, ή/και εστέρα αυτής, συνθέσεις που περιέχουν τέτοιες ενώσεις, θεραπευτικές μεθόδους που περιλαμβάνουν τη χορήγηση τέτοιων ενώσεων, και θεραπευτικές μεθόδους και περιλαμβάνουν τη χορήγηση τέτοιων ενώσεων με τουλάχιστον έναν επιπρόσθετο θεραπευτικό παράγοντα.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90322807P | 2007-02-23 | 2007-02-23 | |
US95871607P | 2007-07-06 | 2007-07-06 | |
EP08743531.9A EP2118082B1 (en) | 2007-02-23 | 2008-02-22 | Modulators of pharmacokinetic properties of therapeutics |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1118292T1 true CY1118292T1 (el) | 2017-06-28 |
Family
ID=39522375
Family Applications (9)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20161101075T CY1118292T1 (el) | 2007-02-23 | 2016-10-25 | Ρυθμιστες φαρμακοκινητικων ιδιοτητων των θεραπευτικων |
CY20161101152T CY1118219T1 (el) | 2007-02-23 | 2016-11-09 | Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων |
CY20161101168T CY1118227T1 (el) | 2007-02-23 | 2016-11-14 | Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων |
CY20161101170T CY1118232T1 (el) | 2007-02-23 | 2016-11-15 | Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων |
CY2017003C CY2017003I2 (el) | 2007-02-23 | 2017-01-04 | Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων |
CY2017001C CY2017001I2 (el) | 2007-02-23 | 2017-01-04 | Ρυθμιστες φαρμακοκινητικων ιδιοτητων των θεραπευτικων |
CY2017002C CY2017002I2 (el) | 2007-02-23 | 2017-01-04 | Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων |
CY20201100220T CY1122761T1 (el) | 2007-02-23 | 2020-03-13 | Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων |
CY2020011C CY2020011I2 (el) | 2007-02-23 | 2020-06-05 | Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων |
Family Applications After (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20161101152T CY1118219T1 (el) | 2007-02-23 | 2016-11-09 | Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων |
CY20161101168T CY1118227T1 (el) | 2007-02-23 | 2016-11-14 | Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων |
CY20161101170T CY1118232T1 (el) | 2007-02-23 | 2016-11-15 | Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων |
CY2017003C CY2017003I2 (el) | 2007-02-23 | 2017-01-04 | Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων |
CY2017001C CY2017001I2 (el) | 2007-02-23 | 2017-01-04 | Ρυθμιστες φαρμακοκινητικων ιδιοτητων των θεραπευτικων |
CY2017002C CY2017002I2 (el) | 2007-02-23 | 2017-01-04 | Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων |
CY20201100220T CY1122761T1 (el) | 2007-02-23 | 2020-03-13 | Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων |
CY2020011C CY2020011I2 (el) | 2007-02-23 | 2020-06-05 | Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων |
Country Status (32)
Country | Link |
---|---|
US (7) | US9891239B2 (el) |
EP (5) | EP3689353A1 (el) |
JP (9) | JP4881446B2 (el) |
KR (2) | KR101664154B1 (el) |
CN (2) | CN103435570B (el) |
AP (2) | AP3915A (el) |
AR (1) | AR065439A1 (el) |
AU (1) | AU2008218186C1 (el) |
BR (1) | BRPI0807581A2 (el) |
CA (1) | CA2678907C (el) |
CY (9) | CY1118292T1 (el) |
DK (2) | DK2487166T3 (el) |
EA (1) | EA019893B1 (el) |
ES (6) | ES2525454T3 (el) |
FI (1) | FI2487161T4 (el) |
FR (1) | FR20C1021I1 (el) |
HK (1) | HK1137451A1 (el) |
HR (5) | HRP20161476T4 (el) |
HU (6) | HUE029866T2 (el) |
IL (1) | IL200550A0 (el) |
LT (9) | LT2487163T (el) |
LU (1) | LUC00156I2 (el) |
MX (1) | MX2009008935A (el) |
NO (4) | NO2017002I2 (el) |
NZ (1) | NZ579802A (el) |
PL (3) | PL2487162T3 (el) |
PT (6) | PT2487163T (el) |
SG (2) | SG10201705929QA (el) |
SI (1) | SI3150586T1 (el) |
TW (1) | TWI533868B (el) |
WO (1) | WO2008103949A1 (el) |
ZA (1) | ZA200905882B (el) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA05011297A (es) | 2003-04-25 | 2006-05-25 | Gilead Sciences Inc | Analogos antivirales de fosfonato. |
ES2363160T3 (es) * | 2004-07-27 | 2011-07-22 | Gilead Sciences, Inc. | Conjugados de fosfonato nucelosidico como agentes anti-vih. |
KR101636221B1 (ko) | 2006-07-07 | 2016-07-04 | 길리애드 사이언시즈, 인코포레이티드 | 치료제의 약동학 특성의 모듈레이터 |
CA2661873A1 (en) * | 2006-08-31 | 2008-03-06 | Abbott Laboratories | Cytochrome p450 oxidase inhibitors and uses thereof |
ES2525454T3 (es) | 2007-02-23 | 2014-12-23 | Gilead Sciences, Inc. | Moduladores de las propiedades farmacocinéticas de agentes terapéuticos |
SI2487162T1 (sl) | 2007-02-23 | 2016-12-30 | Gilead Sciences, Inc. | Modulatorji farmakokinetičnih lastnosti terapevtskih sredstev |
WO2009067225A2 (en) * | 2007-11-20 | 2009-05-28 | Concert Pharmaceuticals, Inc. | Boceprevir derivatives for the treatment of hcv infections |
EP2231628B1 (en) * | 2008-01-04 | 2015-10-28 | Gilead Sciences, Inc. | Inhibitors of cytochrome p450 |
DK2296633T3 (en) * | 2008-05-02 | 2016-01-11 | Gilead Sciences Inc | USE OF SOLID CARRIER PARTICLES TO IMPROVE THE PREPARABILITY OF A PHARMACEUTICAL AGENT |
JP5620376B2 (ja) | 2008-07-08 | 2014-11-05 | ギリアード サイエンシーズ, インコーポレイテッド | Hiv阻害剤化合物の塩 |
CN103497192B (zh) | 2008-12-09 | 2015-09-23 | 吉里德科学公司 | Toll样受体调节剂 |
HUE025822T2 (en) * | 2009-02-06 | 2016-04-28 | Gilead Sciences Inc | Dual layer tablets containing Elvitegravir, Cobicistat, Emtricitabine and Tenofovir |
AU2015200637C1 (en) * | 2009-02-06 | 2017-08-03 | Gilead Sciences, Inc. | Tablets for combination therapy |
UA108738C2 (uk) * | 2009-04-03 | 2015-06-10 | Спосіб одержання інгібітора цитохром р450 монооксигенази та залучені проміжні сполуки | |
WO2010151672A2 (en) * | 2009-06-26 | 2010-12-29 | Georgetown University | Amino acid derived ureas |
SG10201707183TA (en) | 2010-01-27 | 2017-10-30 | Viiv Healthcare Co | Antiviral therapy |
NL2005306C2 (nl) * | 2010-09-02 | 2012-03-05 | Tersia Nederland B V | Koppelstuk voor meerlaagse leidingen, lasapparaaat voor het verbinden van het koppelstuk met meerlaagse leidingen, werkwijze van koppelen en een samenstel verkregen via de werkwijze. |
WO2012045007A1 (en) | 2010-10-01 | 2012-04-05 | Gilead Sciences, Inc. | Method of preparation of (4 - {4 -acetylamino- 2 - [3- ( 2 - isopropyl - thiazol - 4 - ylmethyl) - 3 -methyl - ureido] - butyryl amino} -1 -benzyl- 5 -phenyl- pentyl) -carbamic acid thiazol - 5 - ylmethyl ester |
PT2640362E (pt) * | 2010-11-19 | 2014-11-28 | Gilead Sciences Inc | Composições terapêuticas compreendendo hcl de rilpivirina e tenofovir disoproxil fumarato |
WO2012088156A1 (en) | 2010-12-21 | 2012-06-28 | Gilead Sciences, Inc. | Inhibitors of cytochrome p450 |
US20130280212A1 (en) * | 2010-12-21 | 2013-10-24 | Gilead Sciences, Inc | Inhibitors of cytochrome p450 |
US20130274254A1 (en) | 2010-12-21 | 2013-10-17 | Gilead Sciences, Inc. | Inhibitors of cytochrome p450 (cyp3a4) |
EP2472320A2 (en) | 2010-12-30 | 2012-07-04 | Rohm and Haas Electronic Materials LLC | Compositions comprising base-reactive component and processes for photolithography |
PT2705027E (pt) * | 2011-05-02 | 2015-09-11 | Gilead Sciences Inc | Sais sólido de amorfo de cobicistat (gs-9350) |
CN103826616B (zh) | 2011-07-07 | 2016-08-10 | 爱尔兰詹森科学公司 | 地瑞纳韦组合配制品 |
EP3070088A1 (en) | 2011-08-16 | 2016-09-21 | Gilead Sciences, Inc. | Tenofovir alafenamide hemifumarate |
MX2014009344A (es) | 2012-02-03 | 2015-05-11 | Gilead Sciences Inc | Metodos e intermediarios para preparar agentes farmaceuticos. |
WO2013115916A1 (en) * | 2012-02-03 | 2013-08-08 | Gilead Sciences, Inc. | Combination therapy comprising gs-7340 and cobicistat for use in the treatment of viral infections |
AU2013204727A1 (en) * | 2012-02-03 | 2013-08-22 | Gilead Sciences, Inc. | Therapeutic compounds |
CN103694196A (zh) * | 2012-09-27 | 2014-04-02 | 上海迪赛诺化学制药有限公司 | 细胞色素p450单加氧酶抑制剂中间体及其制法和用途 |
WO2014057498A2 (en) | 2012-10-08 | 2014-04-17 | Mylan Laboratories Ltd. | Process for the preparation of cobicistat intermediates |
JP2015534973A (ja) * | 2012-10-23 | 2015-12-07 | シプラ・リミテッド | 抗レトロウイルス医薬組成物 |
LT3067358T (lt) | 2012-12-21 | 2019-11-25 | Gilead Sciences Inc | Policikliniai karbamoilpiridono junginiai ir jų farmacinis panaudojimas |
JP2016504364A (ja) | 2012-12-26 | 2016-02-12 | アッシア・ケミカル・インダストリーズ・リミテッド | コビシスタット塩 |
NO2865735T3 (el) | 2013-07-12 | 2018-07-21 | ||
SI3019503T1 (sl) | 2013-07-12 | 2017-11-30 | Gilead Sciences, Inc. | Policiklične karbamoilpiridonske spojine in njihova uporaba za zdravljenje HIV infekcij |
EA031172B1 (ru) | 2013-10-07 | 2018-11-30 | Бристол-Майерс Сквибб Холдингс Айэрланд | Состав для лечения вич-инфекции на основе атазанавира и кобицистата |
ES2689654T3 (es) | 2013-12-03 | 2018-11-15 | Mylan Laboratories Ltd. | Preparación de productos intermedios de cobicistat |
WO2015145324A1 (en) | 2014-03-25 | 2015-10-01 | Mylan Laboratories Ltd | Process for the preparation of cobicistat |
NO2717902T3 (el) | 2014-06-20 | 2018-06-23 | ||
TWI677489B (zh) | 2014-06-20 | 2019-11-21 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
WO2016007765A1 (en) | 2014-07-11 | 2016-01-14 | Gilead Sciences, Inc. | Modulators of toll-like receptors for the treatment of hiv |
AP2017009724A0 (en) * | 2014-07-17 | 2017-01-31 | Chdi Foundation Inc | Methods and compositions for treating hiv-related disorders |
UY36298A (es) | 2014-09-16 | 2016-04-29 | Gilead Science Inc | Formas sólidas de un modulador del receptor tipo toll |
TWI695003B (zh) | 2014-12-23 | 2020-06-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
AU2015370004B2 (en) | 2014-12-26 | 2021-03-11 | Emory University | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
SI3466490T1 (sl) | 2015-04-02 | 2020-12-31 | Gilead Sciences, Inc. | Policiklične spojine karbamoilpiridona in njihova farmacevtska uporaba |
CN105198829B (zh) * | 2015-08-15 | 2017-10-31 | 浙江永宁药业股份有限公司 | 一种可比司他中间体的制备方法及其中间体和用途 |
CN107513046B (zh) * | 2016-06-15 | 2019-12-13 | 江苏欧信制药有限公司 | 一种可比司他的合成方法 |
AU2017305303B2 (en) * | 2016-08-04 | 2020-05-28 | Gilead Sciences, Inc. | Cobicistat for use in cancer treatments |
ES2952878T3 (es) | 2016-08-08 | 2023-11-06 | Hetero Labs Ltd | Una composición antirretroviral multiclase |
BR112019002132A2 (pt) | 2016-08-08 | 2019-05-14 | Hetero Labs Limited | composições anti-retrovirais |
KR101908853B1 (ko) * | 2017-05-17 | 2018-10-16 | 경북대학교 산학협력단 | 아세틸시코닌을 유효성분으로 함유하는 시토크롬 p450 동효소 억제용 조성물 |
US10851125B2 (en) | 2017-08-01 | 2020-12-01 | Gilead Sciences, Inc. | Crystalline forms of ethyl ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl(-L-alaninate |
SG11202004403QA (en) | 2017-12-07 | 2020-06-29 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
CN109912530A (zh) * | 2017-12-13 | 2019-06-21 | 上海奥博生物医药技术有限公司 | 一种可比司他原料杂质的制备方法 |
CA3089388A1 (en) * | 2018-01-30 | 2019-08-08 | Sun Biopharma, Inc. | Methods for producing (6s,15s)-3,8,13,18-tetraazaicosane-6,15-diol |
WO2021209563A1 (en) | 2020-04-16 | 2021-10-21 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus |
CN117105928B (zh) * | 2023-08-22 | 2024-03-26 | 上海蓝木化工有限公司 | 一种蛋白酶抑制剂及其制备方法 |
Family Cites Families (129)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US108617A (en) * | 1870-10-25 | Improvement in ore-pulverizers | ||
US181902A (en) * | 1876-09-05 | Improvement in bell toys | ||
US115665A (en) * | 1871-06-06 | Improvement in folding-steps for carriages | ||
US77295A (en) * | 1868-04-28 | theqdoee krausch | ||
US191319A (en) * | 1877-05-29 | Improvement in stoves | ||
US199851A (en) * | 1878-01-29 | Improvement in circular saws | ||
US127689A (en) * | 1872-06-11 | Improvement in differential pulley-blocks | ||
US143314A (en) * | 1873-09-30 | Improvement in condenser-tube fastenings | ||
US99902A (en) * | 1870-02-15 | 1870-02-15 | Improvement in adjustable dials for travelers watches | |
US3400197A (en) | 1965-01-26 | 1968-09-03 | Robins Co Inc A H | Compressible sustained release pharmaceutical tablet lipid-colloidal silica gel matrix fragment granules |
US3882114A (en) | 1967-10-26 | 1975-05-06 | Oreal | N-(morpholinomethyl carbamyl) cysteamine and glycine |
GB1241024A (en) | 1968-10-29 | 1971-07-28 | Boehringer Sohn Ingelheim | Pharmaceutical tablet base and a process for its manufacture |
FR2096292A5 (el) | 1970-06-15 | 1972-02-11 | Sumitomo Chemical Co | |
GB1339764A (en) | 1971-03-29 | 1973-12-05 | Ici Ltd | Pyridine derivatives |
CH586568A5 (el) | 1972-04-10 | 1977-04-15 | Hoffmann La Roche | |
US3957774A (en) | 1972-04-17 | 1976-05-18 | L'oreal | N-morpholinomethyl-n-'-substituted ethyl and propylureas |
DE2845326C2 (de) | 1978-10-18 | 1985-05-23 | Beiersdorf Ag, 2000 Hamburg | Verwendung einer spezifischen mikrodispersen, amorphen, porösen Kieselsäure zur Herstellung von Digoxin enthaltenden Tabletten mit stark beschleunigter Wirkstoff-Freisetzung |
US5142056A (en) * | 1989-05-23 | 1992-08-25 | Abbott Laboratories | Retroviral protease inhibiting compounds |
HU186777B (en) | 1981-07-09 | 1985-09-30 | Magyar Tudomanyos Akademia | Process for producing complex-forming agents of crown-ether base and ionoselective membranelektrodes containing them |
US4603143A (en) | 1983-05-02 | 1986-07-29 | Basf Corporation | Free-flowing, high density, fat soluble vitamin powders with improved stability |
GB8413191D0 (en) | 1984-05-23 | 1984-06-27 | Beecham Group Plc | Pharmaceutical composition |
FR2631620B1 (fr) | 1988-05-19 | 1990-07-27 | Rhone Poulenc Chimie | Nouvelle silice precipitee absorbante et composition a base de cette s ilice |
US5539122A (en) * | 1989-05-23 | 1996-07-23 | Abbott Laboratories | Retroviral protease inhibiting compounds |
US5362912A (en) * | 1989-05-23 | 1994-11-08 | Abbott Laboratories | Process for the preparation of a substituted diaminodiol |
US5354866A (en) | 1989-05-23 | 1994-10-11 | Abbott Laboratories | Retroviral protease inhibiting compounds |
EP0428849A3 (en) | 1989-09-28 | 1991-07-31 | Hoechst Aktiengesellschaft | Retroviral protease inhibitors |
US6703396B1 (en) * | 1990-02-01 | 2004-03-09 | Emory University | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
US6642245B1 (en) | 1990-02-01 | 2003-11-04 | Emory University | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
US5204466A (en) * | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
IE20010533A1 (en) * | 1990-11-20 | 2003-03-05 | Abbott Lab | Intermediates for preparing retroviral protease inhibiting compounds |
GB9109862D0 (en) | 1991-05-08 | 1991-07-03 | Beecham Lab Sa | Pharmaceutical formulations |
JPH06127981A (ja) | 1992-03-03 | 1994-05-10 | Fuainiteii Kk | 複合複層ガラス及びそれを使用した窓 |
US5968942A (en) | 1992-08-25 | 1999-10-19 | G. D. Searle & Co. | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
DK1302468T3 (da) | 1992-12-29 | 2009-03-02 | Abbott Lab | Fremgangsmåder og mellemprodukter til fremstilling af forbindelser, der inhiberer retroviral protease |
WO1995005808A1 (en) | 1993-08-24 | 1995-03-02 | Abbott Laboratories | Oil-based tableting method |
US5567592A (en) | 1994-02-02 | 1996-10-22 | Regents Of The University Of California | Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal |
US5585115A (en) | 1995-01-09 | 1996-12-17 | Edward H. Mendell Co., Inc. | Pharmaceutical excipient having improved compressability |
US5567823A (en) | 1995-06-06 | 1996-10-22 | Abbott Laboratories | Process for the preparation of an HIV protease inhibiting compound |
US6037157A (en) | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
US5763464A (en) | 1995-11-22 | 1998-06-09 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Retroviral agents containing anthranilamide, substituted benzamide and other subunits, and methods of using same |
JP4064476B2 (ja) | 1996-03-29 | 2008-03-19 | エラワン ファーマスーティカル リサーチ アンドラボラトリー カンパニー リミテッド | 二酸化珪素を有する球状凝集した澱粉 |
US6348216B1 (en) | 1996-06-10 | 2002-02-19 | Knoll Pharmaceutical Company | Ibuprofen and narcotic analgesic compositions |
US6361794B1 (en) | 1996-06-12 | 2002-03-26 | Basf Corporation | Method of making ibuprofen and narcotic analgesic composition |
US5922695A (en) * | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
US5939090A (en) | 1996-12-03 | 1999-08-17 | 3M Innovative Properties Company | Gel formulations for topical drug delivery |
JP4494539B2 (ja) | 1997-02-28 | 2010-06-30 | ディーエスエム アイピー アセッツ ビー.ブイ. | 流動自由な乾燥粒子 |
US5935946A (en) * | 1997-07-25 | 1999-08-10 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
FR2767071B1 (fr) | 1997-08-06 | 1999-09-10 | Rhodia Chimie Sa | Composition comprenant un liquide absorbe sur un support a base de silice precipitee |
WO1999033792A2 (en) * | 1997-12-24 | 1999-07-08 | Vertex Pharmaceuticals Incorporated | Prodrugs os aspartyl protease inhibitors |
FR2773994B1 (fr) | 1998-01-23 | 2002-10-11 | Univ Nice Sophia Antipolis | Prodrogues issues d'anti-proteases inhibitrices du virus de l'immunodeficience humaine (vih) pour l'amelioration de leur biodisponibilite, de leur tropisme vers et/ou de leur delivrance dans le systeme nerveux central |
JP4027535B2 (ja) | 1998-05-26 | 2007-12-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 脂溶性薬物を含有した粉末 |
US6342249B1 (en) | 1998-12-23 | 2002-01-29 | Alza Corporation | Controlled release liquid active agent formulation dosage forms |
TR200103488T2 (tr) * | 1999-06-04 | 2002-04-22 | Abbott Laboratories | Geliştirilmiş farmasötik formülasyonlar. |
RU2247123C2 (ru) | 1999-10-06 | 2005-02-27 | Тиботек Фармасьютикалз Лтд. | Гексагидрофуро [2,3-b] фуран-3-ил-n-{3-[(1,3-бензодиоксол-5- илсульфонил)(изобутил)амино]-1-бензил -2-гидроксипропил}карбамат, фармацевтическая композиция на их основе, способы ингибирования и способ лечения |
CA2311734C (en) | 2000-04-12 | 2011-03-08 | Bristol-Myers Squibb Company | Flash-melt oral dosage formulation |
US6448245B1 (en) | 2000-05-04 | 2002-09-10 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of and compounds for inhibiting calpains |
US20030035834A1 (en) | 2000-05-26 | 2003-02-20 | Pawan Seth | Sustained release verapamil pharmaceutical composition free of food effect and a method for alleviating food effect in drug release |
KR20030040389A (ko) | 2000-09-19 | 2003-05-22 | 다이이찌 세이야꾸 가부시기가이샤 | 의약 조성물 |
US7056951B2 (en) | 2000-09-26 | 2006-06-06 | Mutual Pharmaceutical Co., Inc. | Stable solid dosage forms of amino acids and processes for producing same |
US6524615B2 (en) | 2001-02-21 | 2003-02-25 | Kos Pharmaceuticals, Incorporated | Controlled release pharmaceutical composition |
DE10112651A1 (de) | 2001-03-16 | 2002-09-19 | Degussa | Inhomogene Kieselsäuren als Trägermaterial |
BR0209283A (pt) | 2001-05-01 | 2004-07-13 | Pfizer Prod Inc | Método para a fabricação de uma composição farmacêutica de baixa dosagem tendo distribuição e potência de droga uniforme |
DE10126163A1 (de) | 2001-05-30 | 2002-12-05 | Degussa | Pharmazeutische Zubereitungen |
JP4570357B2 (ja) | 2001-07-06 | 2010-10-27 | ライフサイクル ファーマ エー/エス | 制御された凝集 |
US6946449B2 (en) | 2001-07-13 | 2005-09-20 | Cv Therapeutics, Inc. | Partial and full agonists of A1 adenosine receptors |
US7193065B2 (en) | 2001-07-13 | 2007-03-20 | Roche Diagnostics Operations, Inc. | Protease inhibitor conjugates and antibodies useful in immunoassay |
GB0123400D0 (en) | 2001-09-28 | 2001-11-21 | Novartis Ag | Organic compounds |
US7815936B2 (en) | 2001-10-30 | 2010-10-19 | Evonik Degussa Gmbh | Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions |
US20030206978A1 (en) | 2001-11-29 | 2003-11-06 | Bob Sherwood | Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose |
WO2003047551A1 (en) | 2001-11-29 | 2003-06-12 | Penwest Pharmaceutical Company | Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose |
US7285566B2 (en) * | 2002-01-07 | 2007-10-23 | Erickson John W | Resistance-repellent retroviral protease inhibitors |
ATE370948T1 (de) * | 2002-01-17 | 2007-09-15 | Merck & Co Inc | Hydroxynaphthyridinoncarbonsäureamide, die sich als inhibitoren der hiv-integrase eignen |
US6926906B2 (en) | 2002-02-20 | 2005-08-09 | M./S. Strides, Inc. | Orally administrable pharmaceutical formulation |
US6726448B2 (en) | 2002-05-15 | 2004-04-27 | General Electric Company | Ceramic turbine shroud |
PA8576201A1 (es) | 2002-07-10 | 2004-05-26 | Pfizer Prod Inc | Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco |
DE10250711A1 (de) | 2002-10-31 | 2004-05-19 | Degussa Ag | Pharmazeutische und kosmetische Zubereitungen |
EP2272516A3 (en) * | 2002-11-20 | 2011-03-16 | Japan Tobacco, Inc. | 4-Oxoquinoline compound and use thereof as HIV integrase inhibitor |
US7189416B2 (en) | 2002-11-23 | 2007-03-13 | Glykon Technologies Group, Llc | Method for stable and controlled delivery of (-)-hydroxycitric acid |
JP2004184681A (ja) | 2002-12-03 | 2004-07-02 | Konica Minolta Holdings Inc | 熱現像感光材料 |
KR20080032014A (ko) | 2003-01-14 | 2008-04-11 | 길리애드 사이언시즈, 인코포레이티드 | 복합 항바이러스 치료를 위한 조성물 및 방법 |
WO2004073687A1 (en) | 2003-02-19 | 2004-09-02 | H. Lundbeck A/S | Method for preparation of an agglomerate using melt agglomeration |
FR2851918B1 (fr) | 2003-03-06 | 2006-06-16 | Poudre impregnee ameliorant la biodisponibilite et/ou la solubilite et procede de fabrication | |
TW200505441A (en) * | 2003-03-24 | 2005-02-16 | Hoffmann La Roche | Non-nucleoside reverse transcriptase inhibitorsⅠ |
JP4018664B2 (ja) | 2003-04-30 | 2007-12-05 | 第一三共株式会社 | 安定化固形製剤 |
DE10337198A1 (de) | 2003-08-13 | 2005-03-17 | Degussa Ag | Träger auf Basis von Granulaten, die aus pyrogen hergestelltem Siliciumdioxiden hergestellt sind |
US20050048112A1 (en) | 2003-08-28 | 2005-03-03 | Jorg Breitenbach | Solid pharmaceutical dosage form |
US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
JP2005075826A (ja) | 2003-08-29 | 2005-03-24 | Boehringer Ingelheim Internatl Gmbh | 多孔質シリカ担体を含有する徐放性製剤 |
JP2005091988A (ja) | 2003-09-19 | 2005-04-07 | Konica Minolta Medical & Graphic Inc | 熱現像感光材料及び画像形成方法 |
US20070122482A1 (en) | 2003-10-03 | 2007-05-31 | Per Holm | Method for preparing modified release pharmaceutical compositions |
US20050096390A1 (en) | 2003-10-10 | 2005-05-05 | Per Holm | Compositions comprising fenofibrate and pravastatin |
US20050095287A1 (en) | 2003-10-29 | 2005-05-05 | Matharu Amol S. | Fosinopril composition |
US7834043B2 (en) | 2003-12-11 | 2010-11-16 | Abbott Laboratories | HIV protease inhibiting compounds |
US20070298108A1 (en) | 2004-03-01 | 2007-12-27 | Peter Svete | Pharmaceutical Formulation |
MY142989A (en) | 2004-03-10 | 2011-02-14 | Bayer Schering Pharma Ag | Stabilised supersaturated solids of lipophilic drugs |
WO2005105040A2 (en) | 2004-04-26 | 2005-11-10 | Micelle Products, Inc. | Water-soluble formulations of fat soluble vitamins and pharmaceutical agents and their applications |
BRPI0401742B8 (pt) | 2004-05-13 | 2021-05-25 | Cristalia Produtos Quim Farmaceuticos Ltda | composto análogo do ritonavir útil como inibidor de protease retroviral, preparação do composto análogo do ritonavir e composição farmacêutica do composto análogo do ritonavir |
MY134672A (en) | 2004-05-20 | 2007-12-31 | Japan Tobacco Inc | Stable crystal of 4-oxoquinoline compound |
US8633219B2 (en) | 2004-05-21 | 2014-01-21 | Japan Tobacco Inc. | Combination therapy |
JP2006003701A (ja) | 2004-06-18 | 2006-01-05 | Konica Minolta Medical & Graphic Inc | 熱現像感光材料および画像形成方法 |
EP1765297A2 (en) | 2004-06-28 | 2007-03-28 | LifeCycle Pharma A/S | Porous tablets as carriers for liquid formulations |
EP1773850B1 (en) * | 2004-07-06 | 2013-01-30 | Abbott Laboratories | Prodrugs of hiv protease inhibitors |
AR045841A1 (es) | 2004-09-28 | 2005-11-16 | Richmond Sa Com Ind Y Financie | Una composicion farmaceutica solida que comprende al tiazolil metil ester del acido [5s-(5r*, 8r*, 10r*,11r*)] -10- hidroxi-2- metil-5-(1-metiletil)-1-[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis(fenilmetil)-2,4,7,12- tetraazatridecan-13-oico y un procedimiento para prepararla. |
CA2584670A1 (en) | 2004-10-19 | 2006-04-27 | Achillion Pharmaceuticals, Inc. | Combination therapy for treating viral infections |
US7786153B2 (en) | 2005-03-02 | 2010-08-31 | Abbott Laboratories Inc. | Compounds that are useful for improving pharmacokinetics |
TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
US20070014854A1 (en) | 2005-07-15 | 2007-01-18 | Ilan Zalit | Novel granulation process |
BRPI0620578A2 (pt) | 2005-12-27 | 2011-12-06 | Jubilant Organosys Ltd | composição farmacêutica que dissolve na boca e processo para o preparo da mesma |
US20090233964A1 (en) | 2005-12-30 | 2009-09-17 | Gilead Sciences, Inc. | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
EA201201496A1 (ru) | 2005-12-30 | 2013-07-30 | Джилид Сайэнс, Инк. | Способ ингибирования интегразы вич, способ улучшения фармакокинетики 6-(3-хлор-2-фторбензил)-1-[(2s)-1-гидрокси-3-метилбутан-2-ил]-7-метокси-4-оксо-1,4-дигидрохинолин-3-карбоновой кислоты (варианты), набор, фармацевтическая композиция (варианты) и антиретровирусный агент (варианты) |
BRPI0706280A2 (pt) | 2006-01-05 | 2011-03-22 | Lifecycle Pharma As | produto de comprimido carregável desintegrante, e, método para a preparação de um comprimido carregável desintegrante |
CN101384281A (zh) | 2006-02-20 | 2009-03-11 | 朝日啤酒株式会社 | 颗粒、片剂以及它们的制备方法 |
MX2008012225A (es) | 2006-03-23 | 2008-12-03 | Schering Corp | Combinaciones de inhibidores de proteasa de virus de hepatitis c e inhibidores de isoenzima 3a4 del citocromo p450, y metodos de tratamiento relacionados con las mismas. |
KR101636221B1 (ko) | 2006-07-07 | 2016-07-04 | 길리애드 사이언시즈, 인코포레이티드 | 치료제의 약동학 특성의 모듈레이터 |
AU2007283196A1 (en) | 2006-08-10 | 2008-02-14 | Cipla Limited | Antiretroviral solid oral composition |
CA2661873A1 (en) | 2006-08-31 | 2008-03-06 | Abbott Laboratories | Cytochrome p450 oxidase inhibitors and uses thereof |
US20090281132A1 (en) | 2006-09-04 | 2009-11-12 | Kiran Kumar Narsaiah Velaveni | Pharmaceutical formulation for use in hiv therapy |
US7749537B2 (en) | 2006-12-04 | 2010-07-06 | Scolr Pharma, Inc. | Method of forming a tablet |
ES2525454T3 (es) | 2007-02-23 | 2014-12-23 | Gilead Sciences, Inc. | Moduladores de las propiedades farmacocinéticas de agentes terapéuticos |
AU2008270634B2 (en) * | 2007-06-29 | 2014-01-16 | Gilead Sciences, Inc. | Therapeutic compositions and the use thereof |
AR067183A1 (es) | 2007-06-29 | 2009-09-30 | Gilead Sciences Inc | Composiciones terapeuticas y metodos, usos y equipos |
TWI448457B (zh) | 2007-07-06 | 2014-08-11 | Gilead Sciences Inc | 治療劑的藥物動力學性質之調節劑 |
BRPI0821700A2 (pt) | 2007-12-27 | 2015-06-16 | Baxter Int | Métodos para determinar o número de moléculas de polímero fisiologicamente aceitáveis ligadas a uma proteína ou a um complexo de proteína em um conjugado polímero-proteína e para determinar o número de moléculas de polímero fisiologicamente aceitáveis ligadas a uma proteína ou a um complexo de proteína ou livre em solução |
DK2296633T3 (en) * | 2008-05-02 | 2016-01-11 | Gilead Sciences Inc | USE OF SOLID CARRIER PARTICLES TO IMPROVE THE PREPARABILITY OF A PHARMACEUTICAL AGENT |
HUE025822T2 (en) | 2009-02-06 | 2016-04-28 | Gilead Sciences Inc | Dual layer tablets containing Elvitegravir, Cobicistat, Emtricitabine and Tenofovir |
EP2238979A1 (en) | 2009-04-06 | 2010-10-13 | LEK Pharmaceuticals d.d. | Active pharmaceutical ingredient adsorbed on solid support |
WO2013105474A1 (ja) | 2012-01-10 | 2013-07-18 | Jnc株式会社 | 発光層用材料およびこれを用いた有機電界発光素子 |
AU2013204727A1 (en) | 2012-02-03 | 2013-08-22 | Gilead Sciences, Inc. | Therapeutic compounds |
-
2008
- 2008-02-22 ES ES08743531.9T patent/ES2525454T3/es active Active
- 2008-02-22 PL PL12167590T patent/PL2487162T3/pl unknown
- 2008-02-22 AP AP2013007042A patent/AP3915A/en active
- 2008-02-22 AU AU2008218186A patent/AU2008218186C1/en active Active
- 2008-02-22 ES ES12167591.2T patent/ES2603645T3/es active Active
- 2008-02-22 HU HUE12167596A patent/HUE029866T2/en unknown
- 2008-02-22 PT PT121675912T patent/PT2487163T/pt unknown
- 2008-02-22 ES ES12167590.4T patent/ES2603617T3/es active Active
- 2008-02-22 LT LTEP12167591.2T patent/LT2487163T/lt unknown
- 2008-02-22 US US12/528,185 patent/US9891239B2/en active Active
- 2008-02-22 EP EP19219599.8A patent/EP3689353A1/en not_active Withdrawn
- 2008-02-22 SG SG10201705929QA patent/SG10201705929QA/en unknown
- 2008-02-22 AP AP2009004964A patent/AP2986A/xx active
- 2008-02-22 PT PT161805890T patent/PT3150586T/pt unknown
- 2008-02-22 ES ES12167596.1T patent/ES2602784T3/es active Active
- 2008-02-22 PT PT121675961T patent/PT2487166T/pt unknown
- 2008-02-22 BR BRPI0807581-6A2A patent/BRPI0807581A2/pt not_active Application Discontinuation
- 2008-02-22 JP JP2009551044A patent/JP4881446B2/ja active Active
- 2008-02-22 PL PL16180589T patent/PL3150586T3/pl unknown
- 2008-02-22 PT PT121675904T patent/PT2487162T/pt unknown
- 2008-02-22 PT PT87435319T patent/PT2118082E/pt unknown
- 2008-02-22 NZ NZ579802A patent/NZ579802A/en unknown
- 2008-02-22 TW TW097106375A patent/TWI533868B/zh active
- 2008-02-22 MX MX2009008935A patent/MX2009008935A/es active IP Right Grant
- 2008-02-22 LT LTEP12167596.1T patent/LT2487166T/lt unknown
- 2008-02-22 HU HUE12167590A patent/HUE029842T2/en unknown
- 2008-02-22 LT LTEP12167590.4T patent/LT2487162T/lt unknown
- 2008-02-22 CN CN201310326757.5A patent/CN103435570B/zh active Active
- 2008-02-22 HU HUE12167591A patent/HUE029843T2/en unknown
- 2008-02-22 FI FIEP12167589.6T patent/FI2487161T4/fi active
- 2008-02-22 US US12/036,124 patent/US8148374B2/en active Active
- 2008-02-22 PT PT121675896T patent/PT2487161T/pt unknown
- 2008-02-22 DK DK12167596.1T patent/DK2487166T3/en active
- 2008-02-22 EP EP24169258.1A patent/EP4403221A2/en active Pending
- 2008-02-22 LT LTEP12167589.6T patent/LT2487161T/lt unknown
- 2008-02-22 LT LTEP16180589.0T patent/LT3150586T/lt unknown
- 2008-02-22 KR KR1020157011742A patent/KR101664154B1/ko active IP Right Grant
- 2008-02-22 HU HUE12167589A patent/HUE031707T2/en unknown
- 2008-02-22 CN CN2008800132554A patent/CN101679325B/zh active Active
- 2008-02-22 SG SG2012054037A patent/SG183059A1/en unknown
- 2008-02-22 HR HRP20161476TT patent/HRP20161476T4/hr unknown
- 2008-02-22 CA CA2678907A patent/CA2678907C/en active Active
- 2008-02-22 WO PCT/US2008/054788 patent/WO2008103949A1/en active Application Filing
- 2008-02-22 ES ES16180589T patent/ES2779826T3/es active Active
- 2008-02-22 PL PL12167589.6T patent/PL2487161T5/pl unknown
- 2008-02-22 DK DK16180589.0T patent/DK3150586T3/da active
- 2008-02-22 SI SI200832112T patent/SI3150586T1/sl unknown
- 2008-02-22 ES ES12167589.6T patent/ES2601820T3/es active Active
- 2008-02-22 EA EA200901155A patent/EA019893B1/ru unknown
- 2008-02-22 EP EP08743531.9A patent/EP2118082B1/en active Active
- 2008-02-22 EP EP12167589.6A patent/EP2487161B2/en active Active
- 2008-02-22 KR KR1020097019921A patent/KR101577698B1/ko active IP Right Grant
- 2008-02-22 EP EP16180589.0A patent/EP3150586B1/en active Active
- 2008-02-22 AR ARP080100737A patent/AR065439A1/es not_active Application Discontinuation
-
2009
- 2009-08-23 IL IL200550A patent/IL200550A0/en unknown
- 2009-08-25 ZA ZA2009/05882A patent/ZA200905882B/en unknown
-
2010
- 2010-04-28 HK HK10104142.7A patent/HK1137451A1/xx unknown
-
2011
- 2011-08-23 JP JP2011181974A patent/JP5554300B2/ja active Active
- 2011-11-21 US US13/301,642 patent/US8486942B2/en active Active
-
2013
- 2013-07-03 US US13/935,117 patent/US20140017199A1/en not_active Abandoned
-
2014
- 2014-02-13 JP JP2014025059A patent/JP2014088441A/ja not_active Withdrawn
- 2014-11-04 US US14/532,868 patent/US20150139948A1/en not_active Abandoned
-
2015
- 2015-01-28 JP JP2015013971A patent/JP6147282B2/ja active Active
- 2015-08-03 US US14/817,068 patent/US20160069915A1/en not_active Abandoned
-
2016
- 2016-04-05 JP JP2016075593A patent/JP6147388B2/ja active Active
- 2016-07-05 JP JP2016132990A patent/JP6192776B2/ja active Active
- 2016-10-20 HR HRP20161371TT patent/HRP20161371T1/hr unknown
- 2016-10-25 CY CY20161101075T patent/CY1118292T1/el unknown
- 2016-11-01 US US15/340,538 patent/US20170158647A1/en not_active Abandoned
- 2016-11-02 HR HRP20161428TT patent/HRP20161428T1/hr unknown
- 2016-11-09 CY CY20161101152T patent/CY1118219T1/el unknown
- 2016-11-14 HR HRP20161502TT patent/HRP20161502T1/hr unknown
- 2016-11-14 CY CY20161101168T patent/CY1118227T1/el unknown
- 2016-11-15 CY CY20161101170T patent/CY1118232T1/el unknown
- 2016-12-12 HU HUS1600054C patent/HUS1600054I1/hu unknown
- 2016-12-16 LT LTPA2016039C patent/LTC2487163I2/lt unknown
- 2016-12-16 LT LTPA2016040C patent/LTC2487162I2/lt unknown
- 2016-12-16 LT LTPA2016038C patent/LTC2487166I2/lt unknown
-
2017
- 2017-01-04 CY CY2017003C patent/CY2017003I2/el unknown
- 2017-01-04 CY CY2017001C patent/CY2017001I2/el unknown
- 2017-01-04 CY CY2017002C patent/CY2017002I2/el unknown
- 2017-01-12 NO NO2017002C patent/NO2017002I2/no unknown
- 2017-01-12 NO NO2017003C patent/NO2017003I1/no unknown
- 2017-01-12 NO NO2017001C patent/NO2017001I1/no unknown
- 2017-07-11 JP JP2017135437A patent/JP2017171695A/ja not_active Withdrawn
-
2019
- 2019-01-17 JP JP2019006234A patent/JP2019059790A/ja not_active Withdrawn
-
2020
- 2020-03-02 HR HRP20200349TT patent/HRP20200349T1/hr unknown
- 2020-03-13 CY CY20201100220T patent/CY1122761T1/el unknown
- 2020-06-02 LU LU00156C patent/LUC00156I2/en unknown
- 2020-06-03 HU HUS2000013C patent/HUS2000013I1/hu unknown
- 2020-06-04 LT LTPA2020508C patent/LTC3150586I2/lt unknown
- 2020-06-05 NO NO2020011C patent/NO2020011I1/no unknown
- 2020-06-05 CY CY2020011C patent/CY2020011I2/el unknown
- 2020-06-17 FR FR20C1021C patent/FR20C1021I1/fr active Active
- 2020-10-08 JP JP2020170304A patent/JP2021001236A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1118292T1 (el) | Ρυθμιστες φαρμακοκινητικων ιδιοτητων των θεραπευτικων | |
CY1116688T1 (el) | Τροποποιητες φαρμακοκινητικων ιδιοτητων θεραπευτικων ειδων | |
CY1124882T1 (el) | Αναλογα 1,4-διϋποκατεστημενης πυριδαζινης και μεθοδοι για την θεραπευτικη αγωγη καταστασεων συναφων με ανεπαρκεια smn | |
PH12018501807A1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of diseas | |
EA200971081A1 (ru) | Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7 | |
CY1118379T1 (el) | Αναστολεις ιου ηπατιτιδας c | |
EA201001669A1 (ru) | Замещенные пиримидин-5-карбоксамиды 281 | |
UY30316A1 (es) | Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones | |
EA201101672A1 (ru) | Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина | |
EA201390908A1 (ru) | Производные бицикло[3.2.1]октиламида и их применение | |
EP2613782A4 (en) | INDAZOLE DERIVATIVES AS INHIBITORS OF THE ERK PATHWAY | |
AR066063A1 (es) | Derivados de triazol que son antagonistas de smo | |
CY1114140T1 (el) | Ενωσεις 4-πυριδινονης και η χρηση αυτων για τον καρκινο | |
BRPI0714885B8 (pt) | compostos terapêuticos e seu uso | |
CY1114163T1 (el) | Μεθοδοι χρησεως ανταγωνιστων αγγειοπιεσινης με παραγοντες χημειοθεραπειας ανθρακυκλινης για να μειωνεται καρδιοτοξικοτητα ή/και να βελτιωνεται επιβιωση | |
PH12015501386A1 (en) | Tricyclic compounds | |
ZA202311035B (en) | Phosphonyl derivative, and composition and pharmaceutical application thereof | |
UY30363A1 (es) | Derivados sustituidos de la n-(3-oxo-2,3-dihidro-1h-isoindol-4-il)-1-naftamida, procesos de preparacion, composiciones farmacéuticas y aplicaciones | |
UY29134A1 (es) | Sulfonamidas sustituidas por derivados de bencimidazol, composiciones que la contienen, procedimiento de preparacion y aplicaciones | |
MX2020008230A (es) | Derivados de ester butanoico sustituido con bisfenilo como inhibidores de nep. | |
UA101312C2 (ru) | Модуляторы фармакокинетических свойств терапевтических препаратов | |
CY1115013T1 (el) | Διαμορφωτες υποδοχεα 7 που προσομοιαζει toll | |
CO6680616A2 (es) | Compuestos de tiofeno 2.3.5- trisustituidos y usos de los mismos | |
UA97112C2 (ru) | Модуляторы фармакокинетических свойств лекарственных средств | |
RS54022B1 (en) | COMPOSITION OF VIRUS INHIBITOR FOR INVIVE THERAPEUTIC USE |